Science & Innovation

Poster and Presentation

Peer Reviewed Publications

HuaTangNing(华堂宁®)

Investor Relations

Investor Center

Corporate Governance

Financial Report

Announcements and Circulars

Listing Documents

Investor Presentation

Investor Calendar

Stock Information

Corporate Communications

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Company Culture

Our Science

> Peer Reviewed Publications

Science & Innovation

Poster and Presentation

Peer Reviewed Publications

Peer Reviewed Publications

Diabetes, Obesity and Metabolism

Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

Diabetes Therapy

Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

Nature Communications

2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

Nature Medicine

2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Clinical and Translational Science

2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Global Journal of Obesity, Diabetes and Metabolic Syndrome

2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

Diabetes, Obesity and Metabolism

2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

Clinical Pharmacokinetics

2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Lancet Diabetes Endocrinology

2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?

Lancet Diabetes Endocrinology

2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Journal of Diabetes Research

2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

2016年第3期《药学进展》：葡萄糖激酶激活剂研究进展

2016年第3期《药学进展》：21世纪2型糖尿病新药研发策略：明鉴病理因素，改善机体功能

Drug Design, Development and Therapy

2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

Intractable & Rare Diseases Research

2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities

Clinical Pharmacokinetics

2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

Intractable & Rare Diseases Research

2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备63392769号-1

沪公网安备 31011502013809号 Privacy Statement Terms of Use

Search

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.

Accept

x

网站首页 CQ9电子